哪里想瘦打哪里！FDA批准Kythera针头药物上市在即

你才双下巴，你全家都双下巴！都是全因之心人皆有之。如果说赘肉是每一个想握有完美外貌的“妹纸”或“汉纸”的大敌，那么一个喜感十足的双下巴称得上是这些人的生死仇敌了。每一分钟，国外都有人为自己的一张大饼脸而深感觉悟，虽然握有一个肉感十足的双下巴捏上去是挺有肉感的，但是还是有很多人的心理素质使其无法承受一个双下巴之重。您可千万别笑，这甚至已经费伊一个庞大的市场需求。根据新泽西州皮肤上外科手术创会的调查研究课题显示，68%的新泽西州人对自己的双下巴表示了“苦恼”之情。而有鉴于此，近期KytheraCorporation向FDA审核了其主要用途消灭双下巴的保健口服双管抑制剂ATX-101。这种抑制剂完成了许多“胖纸”梦寐以求的机制，哪里想瘦打哪里，称得上是不间断减肥。不想以为这种相比之下懦弱的抑制剂只是一个笑话，在FDA其下属的皮肤上和眼科抑制剂特派员会的无记名候选人中会，研究员可是以17：0的超高票数一致拥护其母公司。无论如何是因为这些研究员中会也有很多遭受双下巴之苦吧。FDA也将开发设计计划于本年度的5月13日在此之后对其重申仍要尽快。如果一切顺利的话，KytheraCorporation开发设计计划于本年度下半年将该产品母公司，统计分析外籍人士原计划这一抑制剂的年销售额将超过3亿美元之多。随着保健抑制剂市场需求的日益加大，KytheraCorporation称得上是下了一步好棋。Corporation于去年以8400万美元的价格比从其前携手伙伴拜耳据为己有会收回了这种抑制剂的全部自由权。而KytheraCorporation也想依此为契机在保健抑制剂市场需求中会攻城拔寨。就在上个月，KytheraCorporation和ActelionCorporation达成重要性2700万美元的携手贸易协定，为基础一种失败过的防炎症抑制剂，而这种抑制剂被认为也许开发设计出一种治疗脱发的抑制剂。详述英文名另据：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.